Patents

The following ImmunityBio, Inc. products, platforms and technology are protected by patents in the United States and elsewhere. This website page is provided to satisfy virtual patent marking provisions of various jurisdictions including the virtual patent marking provisions of the America Invents Act. In accordance with Section 287(a) of Title 35 of the United States Code, notice is given. Additional patents and patent applications may also be pending in the United States and internationally.

Aldoxorubicin, aldoxorubicin combinations, or uses thereof

Application Number Grant Number
US 14/893,821 US 10,278,981

Anktiva™ (Nogapendekin Alfa Imbakicept; also known as N-803 or Alt-803), Anktiva™ combinations, or uses thereof

Application Number Grant Number
CN 201410242394.1 CN ZL201410242394.1
CN 201810136797.6  
EP 11178091.2 EP 2388266
EP 15162957.3 EP 2918607
EP 15815782.6 EP 3160498
EP 20152694.4
US 12/700,949 US 8,163,879
US 13/428,776 US 8,940,289
US 13/769,179 US 9,255,141
US 13/854,903 US 9,328,159
US 14/755,989 US 9,925,247
US 15/083,998 US 10,150,805
US 15/254,713 US 10,450,359
US 15/921,512 US 10,537,615
US 16/443,560
US 16/444,807 US 11,173,191
US 16/620,791
US 16/749,955 US 11,046,747
US 16/749,967 US 11,104,716

CD19 t-haNK or uses thereof

Application Number   Grant Number
EP 19882519.2
US 16/969,152

COVID hAd5 Vaccine Platform or uses thereof

Application Number   Grant Number
US 12/651,836   US 8,298,549
US 16/883,263  

Ganitumab or uses thereof

Application Number Grant Number
US 13/891,781 US 8,895,008

hAd5 (E1-,E2b-) Platform or uses thereof

Application Number Grant Number
CN 201680014846.8 CN ZL201680014846.8
CN 201680057188.0
CN 201780046603.7
EP 04814140.2 EP 1697399
EP 08743578.0 EP 2125868
EP 08781241.8 EP 2170384
EP 13773456.2 EP 2895191
EP 16153921.8 EP 3061462
EP 16735415.8
EP 16751434.8
EP 16783793.9 EP 3286213
EP 17807571.9
US 12/528,796 US 8,188,214
US 12/651,836 US 8,298,549
US 13/176,341 US 8,957,192
US 13/622,263
US 14/422,504 US 9,605,276
US 15/433,934 US 10,563,224
US 15/542,005
US 15/564,413 US 11,149,087
US 15/749,214 US 10,550,164
US 16/107,559
US 16/306,097
US 16/458,726 US 10,874,729
US 16/778,043 US 11,034,740

HIV treatments

Application Number   Grant Number
US 16/749,955   US 11,046,747

Nant Cancer Vaccine Platform or uses thereof

Application Number Grant Number
CN 201680014846.8 CN ZL201680014846.8
CN 201680057188.0
EP 04814140.2 EP 1697399
EP 08743578.0 EP 2125868
EP 08781241.8 EP 2170384
EP 13773456.2 EP 2895191
EP 16153921.8 EP 3061462
EP 16751434.8
EP 17821361.7
US 10/738,646 US 7,465,454
US 12/334,729 US 8,153,136
US 12/643,869 US 8,343,502
US 12/651,836 US 8,298,549
US 14/422,504 US 9,605,276
US 14/755,989 US 9,925,247
US 15/542,005
US 15/564,413 US 11,149,087
US 16/312,246 US 11,207,392
US 16/656,293
US 16/778,043 US 11,034,740
US 16/903,882 US 11,000,550
US 16/937,370
US 16/951,739
US 17/217,839 US 11,207,350

NK-92® Cell Platform, NK-92® combinations, or uses thereof

Application Number Grant Number
AU 2013200124 AU 2013200124
AU 2017210556 AU 2017210556
CN 201680019087.4
EP 16773863.2
EP 18763512.3
US 10/008,955 US 10,138,462
US 11/178,258 US 7,618,817
US 15/529,848 US 10,456,420
US 15/914,665 US 10,801,013
US 16/424,201 US 10,774,310
US 16/529,159 US 11,077,143
US 16/529,251 US 10,765,701
US 16/541,847 US 10,736,921
US 16/620,791
US 16/903,882 US 11,000,550
US 16/934,606
US 16/937,370
US 16/940,018
US 17/056,385
US 17/217,839 US 11,207,350

PD-L1 t-haNK or uses thereof

Application Number Grant Number
US 15/914,665 US 10,801,013
US 16/969,152

Yeast Vaccine Platform or uses thereof

Application Number Grant Number
US 10/738,646 US 7,465,454
US 12/334,729 US 8,153,136
US 12/335,094 US 8,067,559
US 12/643,869 US 8,343,502
US 13/803,719 US 9,198,941
US 14/778,118 US 10,507,235
US 14/926,372 US 9,623,097
US 15/454,176 US 10,363,294
US 16/389,235
US 16/951,739